Citi raises Lexicon Pharmaceuticals' price target to $2.10, citing strong momentum from its collaboration with Novo Nordisk on obesity drug candidate LX9851 and improved financials.
The fast-casual salad chain's stock fell sharply this week, pressured by a broader retreat in growth stocks and a reiterated sell call from Goldman Sachs, despite positive signals from the broader restaurant sector.
Reed Jobs, son of the late Apple co-founder Steve Jobs, has secured over $200 million for Yosemite, a venture fund dedicated to pioneering cancer treatments. Backed by major institutions, the fund seeks to transform cancer from a fatal diagnosis to a chronic, manageable disease within a generation.
WisdomTree reports record assets under management of $144.5 billion for 2025, driven by $8.5 billion in net inflows and strategic acquisitions. The firm forecasts continued margin expansion and highlights digital assets, European thematics, and private markets as key growth engines for the coming year.
Standex International reports robust second-quarter results, with organic growth reaching 6.4% and record quarterly orders. The company's strategic pivot towards high-growth markets like electrical grid infrastructure and new product development is now materially boosting the top line.
Standex International reports a robust start to fiscal 2026, with sales climbing 27.6% and a record order book prompting an upward revision of its annual revenue forecast. The company's strategic pivot towards grid modernization and data center markets, highlighted by the rebranded 'Standex Electronics Grid' unit, fuels confidence in exceeding long-term targets.
Standex International reports consecutive quarters of record profitability, driven by strategic acquisitions and growth in electrical grid and aerospace markets, while navigating global trade uncertainties.
President Trump's surprise nomination of former Fed Governor Kevin Warsh to lead the central bank sends mixed signals to investors, stirring debate over future monetary policy and market stability.
Sources indicate OpenAI is accelerating plans for a late-2026 public listing, a move that would place its massive cash burn and long road to profitability under intense investor scrutiny, potentially defining the next phase of the AI boom.
Shares of Cushman & Wakefield have surged 35.8% in six months, dramatically outpacing the broader market. While strong quarterly results fueled the climb, a deeper look at the firm's long-term financial health reveals potential headwinds that could give investors pause.
While Urban Outfitters shares have underperformed the broader market, diving 8.2% over six months, a deeper look reveals a complex picture of robust profitability growth tempered by slowing revenue expansion, leaving investors to weigh its potential against evident risks.
A mixed third-quarter earnings season for therapeutics stocks reveals divergent paths, with United Therapeutics missing estimates while peers like Halozyme and Biogen post strong beats. Sector-wide revenue growth and positive stock reactions suggest underlying investor confidence despite regulatory and pricing headwinds.
Amid escalating tensions and a U.S. military buildup in the Gulf, Iran's foreign minister has declared the country's missile capabilities 'non-negotiable,' setting the stage for a precarious diplomatic standoff.
A trove of documents released by the U.S. Department of Justice includes emails from Jeffrey Epstein making lurid, unsubstantiated allegations about Bill Gates, while also detailing his interactions with other prominent individuals.
Haemonetics (NYSE:HAE) sees its price target raised by Barrington Research following its acquisition of Vivasure Medical, with analysts highlighting the deal's potential to bolster its medical device portfolio and drive growth.
The Cleveland-based RIA platform has appointed three senior executives as its assets under management soar, positioning the firm for its ambitious target of $20 billion by 2027.
Three decades on, Warren Buffett's 1994 shareholder letter, featuring his iconic 'Hope Diamond' analogy, continues to offer a masterclass in capital allocation, challenging the modern obsession with control and highlighting the power of partial ownership in exceptional businesses.
Advocate Health, the nation's third-largest nonprofit health system, is investing over $800 million in enhanced compensation and benefits for its 165,000+ employees, raising its minimum wage and expanding tuition aid, mental health support, and paid volunteer time.
Thermo Fisher Scientific posted stronger-than-expected Q4 revenue and profit, driven by new products and strategic deals. However, the stock fell as investors weighed pressures in key academic and government markets against the company's solid 2026 outlook.
Financial services firm Lazard (LAZ) reported better-than-expected fourth-quarter results, driven by record advisory fees and robust asset growth, signaling resilience in a challenging market.
